WaveMan
WaveMan · Company
GALT · Galectin Therapeutics Inc
> Search tickers & screens ⌘K
LIVE
← All companies

GALT Galectin Therapeutics (GALT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001133416
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
53
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $106.0M priced

What the filings say about GALT

Insiders, 180 days
-$521.7K net sold
2 sellers · 0% of sales under a 10b5-1 plan

Galectin Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, GALECTIN THERAPEUTICS INC insiders sold a net $521.7K of stock across 131 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Jamil Khurram
Chief Medical Officer
SELL
2026-07-16 SECtraded 2026-07-14
16,250
$83.3K
-23.7%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Jun 29, 2026.
  • 1 other insider sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Jamil Khurram sold about $83.3K of GALT on Jul 14, 2026; 1 other insider sold within 30 days and 53 funds added in the latest 13F quarter.
Shlevin Harold H.
Director
SELL
2026-06-30 SECtraded 2026-06-29
22,268
$112.2K
-26.3%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (1 buy, 13 sales), the last on Jun 26, 2026.
  • The trade is 342.6% of the 6,500 shares held after it.
  • 1 other insider sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shlevin Harold H. sold about $112.2K of GALT on Jun 29, 2026; 1 other insider sold within 30 days and 53 funds added in the latest 13F quarter.
Jamil Khurram
Chief Medical Officer
SELL
2026-06-30 SECtraded 2026-06-29
47,467
$239.2K
-26.3%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 26, 2026.
  • 1 other insider sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Jamil Khurram sold about $239.2K of GALT on Jun 29, 2026; 1 other insider sold within 30 days and 53 funds added in the latest 13F quarter.
Shlevin Harold H.
Director
SELL
2026-06-30 SECtraded 2026-06-26
7,732
$38.7K
-26.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (1 buy, 12 sales), the last on Dec 17, 2025.
  • The trade is 119.0% of the 6,500 shares held after it.
  • 1 other insider sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shlevin Harold H. sold about $38.7K of GALT on Jun 26, 2026; 1 other insider sold within 30 days and 53 funds added in the latest 13F quarter.
Jamil Khurram
Chief Medical Officer
SELL
2026-06-30 SECtraded 2026-06-26
2,037
$10.2K
-26.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 23, 2026.
  • 1 other insider sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Jamil Khurram sold about $10.2K of GALT on Jun 26, 2026; 1 other insider sold within 30 days and 53 funds added in the latest 13F quarter.
131 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 126 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$521.7K over 180 days
below 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
53 funds bought in last quarter
below 52% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
19.1% of the float short (float per yahoo 2026-10-27) · 40.0 days to cover · settled 2026-10-15
more than 68% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 8 in the prior 90
Why it matters
The absence is the signal: 8 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch GALT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-37.8%12M
-59%-31%-2%+27%2025-102025-122026-022026-042026-062026-082026-10 2025-12-03 · 10X Capital Management, LLC sold $756.8K2025-12-03 · 10X Capital Management, LLC sold $687.6K2026-06-29 · Jamil Khurram sold $239.2K2025-11-13 · Jamil Khurram sold $227.0K2025-12-08 · Shlevin Harold H. sold $210.7K2025-11-11 · 10X Capital Management, LLC sold $210.0K2025-12-08 · Shlevin Harold H. sold $208.2K2025-12-16 · CZIRR JAMES C sold $204.3K2025-11-18 · CALLICUTT JACK W sold $174.8K2025-12-02 · 10X Capital Management, LLC sold $164.1K2025-12-08 · Shlevin Harold H. sold $148.8K2025-12-17 · Shlevin Harold H. sold $139.3K2026-01-06 · LEWIS JOEL sold $135.0K2025-12-12 · Shlevin Harold H. sold $124.1K2025-12-08 · Shlevin Harold H. sold $120.0K2025-11-13 · Jamil Khurram sold $119.6K2025-12-08 · Shlevin Harold H. sold $119.2K2025-12-08 · Shlevin Harold H. sold $119.2K2025-11-17 · CALLICUTT JACK W sold $118.8K2025-11-18 · CALLICUTT JACK W sold $113.3K2026-06-29 · Shlevin Harold H. sold $112.2K2026-01-05 · LEWIS JOEL sold $108.4K2025-12-09 · Shlevin Harold H. sold $105.3K2026-01-05 · CALLICUTT JACK W sold $100.4K2026-01-05 · Jamil Khurram sold $99.4K2025-11-17 · LEWIS JOEL sold $94.7K2025-11-13 · Jamil Khurram sold $88.9K2025-11-04 · LEWIS JOEL sold $87.5K2026-07-14 · Jamil Khurram sold $83.3K2026-01-06 · Jamil Khurram sold $78.3K2026-01-02 · LEWIS JOEL sold $78.0K2026-01-06 · CALLICUTT JACK W sold $74.7K2025-11-04 · CALLICUTT JACK W sold $65.2K2025-12-17 · Jamil Khurram sold $59.8K2026-01-02 · CALLICUTT JACK W sold $58.4K2025-11-17 · CALLICUTT JACK W sold $57.8K2025-12-17 · LEWIS JOEL sold $55.3K2026-01-02 · Jamil Khurram sold $54.8K2025-11-04 · CALLICUTT JACK W sold $54.5K2025-11-04 · CALLICUTT JACK W sold $54.1K2025-12-15 · Shlevin Harold H. sold $53.0K2025-12-17 · Jamil Khurram sold $45.5K2026-06-29 · Harold Shlevin filed to sell $112.2K2026-06-26 · HAROLD SHLEVIN filed to sell $38.7K2026-06-26 · Jamil Khurram filed to sell $341.4K2026-06-23 · Jamil Khurram filed to sell $25.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GALT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
2,988,353 sh
$13.9M
VANGUARD CAPITAL MANAGEMENT LLC
2,168,065 sh
$10.1M
GEODE CAPITAL MANAGEMENT, LLC
1,308,394 sh
$6.1M
OSAIC HOLDINGS, INC.
1,203,725 sh
$5.6M
MARSHALL WACE, LLP
831,010 sh
$3.9M

Congress trades in GALT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GALT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Harold Shlevin
Filed 2026-06-29
$112.2K
HAROLD SHLEVIN
Filed 2026-06-26
$38.7K
Jamil Khurram
Filed 2026-06-26
$341.4K
Jamil Khurram
Filed 2026-06-23
$25.5K

GALT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Horizon Kinetics Medical ETF
$217.9K position · as of 2026-06-30
1.1%
Invesco NASDAQ Future Gen 200 ETF
$65.0K position · as of 2026-05-31
0.3%
iShares Micro-Cap ETF
$745.1K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$50.0K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$1.4M position · as of 2026-06-30
0.0%
Fidelity Small Cap Growth Index Fund
$142.9K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $521.7K sold by insiders over 180 days, 53 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GALT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-183.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$20.1M-$42.4M-$38.1M-$38.4M
Net income-$30.8M-$47.0M-$41.1M-$38.8M
EPS (diluted)-0.48-0.76-0.74-0.65
Operating cash flow-$23.9M-$41.8M-$33.0M-$31.1M
Cash$17.7M$15.1M$25.7M$18.6M
SEC XBRL, fiscal years, as known on 2026-10-28

GALT Stock Sonar score 3/7 axes

Find similar shapesCompare

GALT ranks highest on institutional and government (48th percentile) and insider conviction (21st), and lowest on risk and compliance (17th), among Pharma & Biotech peers.

Insider conviction
21
Inputs
  • Net Form 4 buying (codes P and S), 180d-$522K · 41 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
48
Inputs
  • Funds adding, latest quarter53 · 48 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
17
Inputs
  • Short interest, % of float+19.2% · 17 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GALT filings, in plain words

Are Galectin Therapeutics insiders buying or selling GALT?

In the 180 days to 2026-10-28, Galectin Therapeutics insiders were net sellers, a net $521.7K across purchases and sales reported on Form 4, by 2 sellers.

Read the full summary

In the 180 days to 2026-10-28, Galectin Therapeutics insiders were net sellers of GALT, a net $521.7K across purchases and sales reported on Form 4 by 2 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies